Expressive Wealth LLC Buys New Position in Gilead Sciences, Inc. $GILD

Expressive Wealth LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 6,869 shares of the biopharmaceutical company’s stock, valued at approximately $868,000. Gilead Sciences comprises 0.8% of Expressive Wealth LLC’s holdings, making the stock its 26th biggest holding.

Several other institutional investors have also added to or reduced their stakes in the business. Laidlaw Wealth Management LLC grew its stake in shares of Gilead Sciences by 74.2% during the second quarter. Laidlaw Wealth Management LLC now owns 2,866 shares of the biopharmaceutical company’s stock worth $362,000 after acquiring an additional 1,221 shares during the last quarter. Shelter Mutual Insurance Co purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $4,057,000. Keebeck Wealth Management purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $418,000. Keating Financial Advisory Services Inc. acquired a new stake in Gilead Sciences in the 2nd quarter worth approximately $352,000. Finally, OneAscent Investment Solutions LLC acquired a new stake in Gilead Sciences in the 2nd quarter worth approximately $286,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on GILD shares. Daiwa Securities Group dropped their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $158.04.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 87,000 shares of company stock worth $11,562,960. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $146.12 on Friday. The business’s 50 day moving average price is $131.97 and its 200 day moving average price is $136.59. The firm has a market cap of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.